Cost cut arrives for game-changer diabetes, obesity drugs

Key Points:

• The Bermuda Diabetes Association (BDA) has introduced generic GLP-1 medications, such as semaglutide (branded as Ozempic), making these previously high-cost diabetes and obesity treatments significantly more affordable for Bermudian patients.
• GLP-1 drugs help manage type 2 diabetes by controlling blood sugar, aiding weight management, reducing cardiovascular risks, and slowing chronic kidney disease progression, but their high branded costs had limited patient access.
• The BDA emphasized that generic versions meet the same quality, safety, and effectiveness standards as branded drugs, and their availability is expected to reduce financial burdens on patients, insurers, and the healthcare system.
• Since 2020, the BDA community pharmacy has saved customers $3.5 million in dispensing fees, with over $400,000 in discounts on high-cost medications, including GLP-1s, demonstrating the impact of affordable generic options.
• Insurer Allshores has also included Ozempic in its coverage under a new partnership, supporting the use of generics to lower healthcare costs and improve diabetes management accessibility in Bermuda.